Cellumed Co. Ltd (049180) - Total Liabilities

Latest as of September 2025: ₩55.10 Billion KRW ≈ $37.34 Million USD

Based on the latest financial reports, Cellumed Co. Ltd (049180) has total liabilities worth ₩55.10 Billion KRW (≈ $37.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cellumed Co. Ltd - Total Liabilities Trend (2008–2024)

This chart illustrates how Cellumed Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 049180 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Cellumed Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Cellumed Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Gyeongnam Steel Co. Ltd
KQ:039240
Korea ₩45.20 Billion
Ihlas Holding AS
IS:IHLAS
Turkey TL18.80 Billion
SCI Information Service Inc
KQ:036120
Korea ₩6.34 Billion
Goldbank Mining Corp
V:GLB
Canada CA$16.21 Million
JERSEY OIL+GAS PLC LS-01
F:TPC1
Germany €147.08K
Youil Energy Technology Co. Ltd.
KQ:340930
Korea ₩125.54 Billion
Electromagnetica SA
RO:ELMA
Romania RON41.97 Million
Akobo Minerals AB (publ)
OL:AKOBO
Norway Nkr316.29 Million

Liability Composition Analysis (2008–2024)

This chart breaks down Cellumed Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Cellumed Co. Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 3.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.77 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cellumed Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cellumed Co. Ltd (2008–2024)

The table below shows the annual total liabilities of Cellumed Co. Ltd from 2008 to 2024.

Year Total Liabilities Change
2024-12-31 ₩61.45 Billion
≈ $41.64 Million
+41.41%
2023-12-31 ₩43.45 Billion
≈ $29.45 Million
+10.54%
2022-12-31 ₩39.31 Billion
≈ $26.64 Million
-18.75%
2021-12-31 ₩48.38 Billion
≈ $32.79 Million
+13.31%
2020-12-31 ₩42.70 Billion
≈ $28.94 Million
-28.59%
2019-12-31 ₩59.80 Billion
≈ $40.53 Million
+125.12%
2018-12-31 ₩26.56 Billion
≈ $18.00 Million
-4.11%
2017-12-31 ₩27.70 Billion
≈ $18.77 Million
+19.24%
2016-12-31 ₩23.23 Billion
≈ $15.74 Million
-42.97%
2015-12-31 ₩40.73 Billion
≈ $27.60 Million
+54.34%
2014-12-31 ₩26.39 Billion
≈ $17.89 Million
-7.64%
2013-12-31 ₩28.57 Billion
≈ $19.36 Million
-15.55%
2012-12-31 ₩33.84 Billion
≈ $22.93 Million
-28.76%
2011-12-31 ₩47.49 Billion
≈ $32.18 Million
+238.53%
2008-12-31 ₩14.03 Billion
≈ $9.51 Million
--

About Cellumed Co. Ltd

KQ:049180 Korea Medical Instruments & Supplies
Market Cap
$37.57 Million
₩55.44 Billion KRW
Market Cap Rank
#22997 Global
#1517 in Korea
Share Price
₩1009.00
Change (1 day)
-9.10%
52-Week Range
₩570.00 - ₩2570.00
All Time High
₩36700.00
About

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more